Today: 20 May 2026
Browse Category

ASX:TLX 11 December 2025 - 10 April 2026

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix Pharmaceuticals shares closed up 14.2% at A$10.43 in Sydney after reporting 2025 revenue rose 56% to US$803.8 million and forecasting 2026 revenue of US$950 million to US$970 million. The company filed for European approval of its TLX101-Px brain cancer imaging agent earlier in the week. Telix ended 2025 with US$141.9 million in cash and posted a US$5.3 million pre-tax loss.
20 February 2026
··
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
21 January 2026
··
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals shares fell 6.61% to A$11.73 on the ASX December 17, with volume at 6.36 million and a 52-week low of A$11.535. Nasdaq-listed shares dropped 6–7% in early U.S. trading. The company issued a statement confirming completion of Part 1 enrollment in its ProstACT Global Phase 3 study after market rumors. TLX591 has not received marketing authorization.
17 December 2025
···
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···

Stock Market Today

  • Nvidia Q1 Earnings Beat Expectations, Shares Dip
    May 20, 2026, 4:32 PM EDT. Nvidia reported Q1 earnings, posting revenue of $81.62 billion, surpassing the $79.19 billion forecast. Adjusted EPS reached $1.87, beating estimates around $1.77-$1.78. Data Center revenue hit $75.2 billion, exceeding predictions. The company provided strong Q2 guidance with revenue expected at $91 billion ±2%, above $87.36 billion estimates, signaling robust AI infrastructure demand despite market concerns. Nvidia's networking segment, critical for AI cluster interconnects, is rapidly expanding, driven by products like NVLink and InfiniBand. This marks a strategic expansion beyond GPUs, including partnerships with Amazon Web Services. However, rising political resistance to data center growth due to environmental and local impact remains a risk. Nvidia shares initially fell 3% post-report.

Latest articles

Royal Bank of Canada Stock Hits 52-Week High — Why May 28 Now Matters

Royal Bank of Canada Stock Hits 52-Week High — Why May 28 Now Matters

20 May 2026
Royal Bank of Canada shares hit a 52-week high of C$257.91 on Wednesday, closing up 1.99% at C$257.55. Fitch upgraded RBC’s legacy senior long-term debt rating to AA+ from AA on May 19. Investors await RBC’s second-quarter results, set for May 28. The S&P/TSX Composite Index rose 0.9% as most sectors advanced.
Arm Jumps 15% as AI CPU Trade Picks Up

Arm Jumps 15% as AI CPU Trade Picks Up

20 May 2026
Arm’s U.S.-listed ADRs jumped 15.1% to $256.73 on Wednesday after Bernstein initiated coverage with an outperform rating and $300 target. The rally came ahead of Nvidia’s results and amid a broader chip stock surge. Arm reported record quarterly revenue and strong demand for its new AGI CPU. Ongoing U.S. antitrust scrutiny and supply constraints remain concerns.
Reddit Pushes Past $150 but Ad Campaign Still Lags

Reddit Pushes Past $150 but Ad Campaign Still Lags

20 May 2026
Reddit shares fell 5.2% to $146.84 late Wednesday, underperforming broader tech indexes despite launching new app-advertising tools. A trust linked to CEO Steve Huffman sold 18,000 shares last week, according to an SEC filing. Reddit reported Q1 revenue of $663 million, up 69% year over year, and set Q2 revenue guidance between $715 million and $725 million.
Go toTop